Is DMK Pharmaceuticals Corporation (DMKPQ) a Buy, Sell, or Hold?
OTC : DMKPQ
DMK Pharmaceuticals Corporation
$0.0001 USD
$0 (0.0%)
- Volume
- 1
- Average Volume
- 3.01K
- Market Capitalization
- $1.01K
- P/E Ratio
- 0.00
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $0.00
- Year Low
- $0.00
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.81
Company Overview
OTC
Eddie Wabern Glover
Drug Manufacturers - Specialty & Generic
Healthcare
DMKPQ
11
US
USD
Liquidity Metrics
-0.53
0.81
0.70
0.09
0.00
Sales & Valuation
$4.76M
0.00
0.00
0.00
-12.42
Profitability
-$12.37
-$26.48M
-556.72%
-550.82%
-209.88%
-242.23%
P/E Metrics
0.00
0.00
0.00
Analyst Price Target & Rating
0/5
0 Analysts
%
Financial Health Scores
-57.71
2/9
-$5.59M
$8.96M
$14.25M
-$18.49M
Key Metrics (TTM)
-$737.79K
-0.16
0.03
0.81
-209.88%
20462.31%
-12368793.95%
-2631774.55%
-236 days
Company Executives
| Name | Title |
|---|---|
| Eddie Wabern Glover | Chief Executive Officer of US Compounding Inc |
| Seth Abraham Cohen | Chief Restructuring Officer |
Poll Results
No votes yet today — be the first to share your view!
About DMK Pharmaceuticals Corporation (OTC:DMKPQ) Stock
DMK Pharmaceuticals Corporation functions as a clinical-stage neuro-biotechnology company, focusing on the development and market introduction of therapeutic solutions across several medical fields, including allergies, opioid overdose, respiratory conditions, and inflammatory diseases. Its primary product candidate currently in clinical trials is DPI-125, designed for the treatment of opioid use disorder. The company's portfolio also encompasses SYMJEPI, an epinephrine injection used for the immediate management of severe allergic reactions (anaphylaxis) triggered by factors such as insect stings, foods, medications, or those that are idiopathic or exercise-induced. Additionally, they offer ZIMHI, a naloxone injection vital for reversing opioid overdoses. The organization, previously name ... d Adamis Pharmaceuticals Corporation, officially rebranded to DMK Pharmaceuticals Corporation in September 2023. Headquartered in San Diego, California, DMK Pharmaceuticals Corporation, along with its associated entities, filed for voluntary Chapter 11 bankruptcy reorganization in the U.S. Bankruptcy Court for the District of Delaware on February 2, 2024.
Frequently Asked Questions
-
What is the current DMK Pharmaceuticals Corporation (DMKPQ) stock price?
-
DMK Pharmaceuticals Corporation(OTC:DMKPQ) stock price is $0.0001 in the last trading session. During the trading session, DMKPQ stock reached the peak price of $0.001 while $0.00001 was the lowest point it dropped to. The percentage change in DMKPQ stock occurred in the recent session was 0.0% while the dollar amount for the price change in DMKPQ stock was $0.
-
DMKPQ's industry and sector of operation?
-
The OTC listed DMKPQ is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector.
-
Who are the executives of DMKPQ?
-
Eddie Wabern Glover | Chief Executive Officer of US Compounding Inc
Seth Abraham Cohen | Chief Restructuring Officer
|
|
| -
How many employees does DMKPQ have?
-
Number of DMKPQ employees currently stands at 11. DMKPQ operates from 11682 El Camino Real, San Diego, CA 92130, US.
-
Link for DMKPQ official website?
-
Official Website of DMKPQ is: https://www.dmkpharmaceuticals.com
-
How do I contact DMKPQ?
-
DMKPQ could be contacted at phone #858 997 2400 and can also be accessed through its website. DMKPQ operates from 11682 El Camino Real, San Diego, CA 92130, US.
-
How many shares of DMKPQ are traded daily?
-
The average number of DMKPQ shares traded daily for last 3 months was 3.01K.
-
What is the market cap of DMKPQ currently?
-
The market value of DMKPQ currently stands at $1.01K with its latest stock price at $0.0001